Pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways driving disease pathogenesis. Lead program, Inebilizumab, is a CD19 mAb which met the primary endpoint in the Ph 2b pivotal study for the treatment of Neuromyelitis Optica. Primary analysis demonstrated a 77% reduction in the risk of developing NMOSD attack in patients treated with inebilizumab monotherapy compared to placebo. BLA filing expected mid-2019. Full global rights to 6 assets (4 clinical, 2 preclinical) from AstraZeneca/Medimmune.
Phase III, Phase l or ll
One MedImmune Way
Fifth Floor, Suite Area Two
Gaithersburg, MD 20878
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.